Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 39 clinical trials
Clinical Study on the Treatment of Recurrent Glioblastoma With Anlotinib

Anlotinib is a novel small molecule multi-target tyrosine kinase inhibitor that can inhibit tumor angiogenesis and inhibit tumor cell growth. We performed second-generation gene sequencing on pathological specimens and cerebrospinal fluid of patients with recurrent glioblastoma.If patients have a genetic mutation VEGFRKitPDGFRFGFRand meet other eligibility criteria, they will be treated …

measurable disease
glioblastoma multiforme
corticosteroids
tumor progression
neutrophil count
  • 0 views
  • 23 Jan, 2021
  • 1 location
The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia

Aim: To evaluate if additional cord blood transfusion could accelerate the hematopoietic reconstitution in severe aplastic anemia(SAA) patients receiving immunosuppressive therapy (IST). Study design: open-labed, prospective, multicenter, randomized control study Number of subjects: 60 each group Treatment IST group: ATG (Thymoglobuline, Genzyme) 3.5mg/kg/d5d plus oral cyclosporine A (CSA) Cord blood …

thymoglobulin
rheumatic heart disease
aplastic anemia
paroxysmal nocturnal hemoglobinuria
immunosuppressant
  • 13 views
  • 24 Jan, 2021
  • 1 location
Switch to Oral Antibiotics in Gram-negative Bacteremia

, central nervous system infection, terminal illness with expected survival less than 14 days, absolute neutrophil count less than 1,000/ml and hematopoietic or solid organ transplantation within the

  • 73 views
  • 23 Jan, 2021
  • 5 locations
Phase 2 Study of Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

This is a Phase 2, open-label, multi-center study to evaluate the efficacy and the safety/tolerability of poziotinib in seven patient cohorts for up to 603 previously treated and treatment-nave NSCLC patients. Cohorts 3 and 4 were added with Amendment 1 and three additional cohorts were added with Amendment 2 (Cohorts …

stage iv non-small cell lung cancer
cancer chemotherapy
erbb2
lung carcinoma
EGFR
  • 320 views
  • 25 Jan, 2021
  • 68 locations
T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas

hepatitis C. At the time of protocol enrollment patients must be seronegative for CMV by antibody testing or must have a negative blood CMV PCR. Absolute neutrophil count greater than or equal to

anaplastic large cell lymphoma
neutrophil count
peripheral t-cell lymphoma
cytokines
cyclophosphamide
  • 1 views
  • 16 Dec, 2020
  • 1 location
EXTEND EXpanding Treatment for Existing Neurological Disease

The primary goal of the Phase II EXTEND trial is to investigate the effects of open-label hydroxyurea treatment, escalated to maximum tolerated dose, for children with Sickle Cell Anemia and either conditional (170 - 199 cm/sec) or abnormal (200 cm/sec) Transcranial Doppler velocities. The primary endpoint will be measured after …

stroke
hydroxyurea
transcranial doppler ultrasonography
anemia
thalassemia
  • 19 views
  • 23 Jan, 2021
  • 1 location
Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma

This randomized phase II trial studies how well stem cell transplant with or without tbo-filgrastim works in treating patients with multiple myeloma or non-Hodgkin lymphoma. Eliminating the use of tbo-filgrastim after transplant may still help maintain a similar time to discharge.

cell transplantation
melphalan
hodgkin's disease
colony stimulating factor
lymphoma
  • 8 views
  • 24 Jan, 2021
  • 1 location
Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant

This phase I/II trial studies the side effects and best dose of gene therapy in treating patients with human immunodeficiency virus (HIV)-related lymphoma that did not respond to therapy or came back after an original response receiving stem cell transplant. In gene therapy, small stretches of deoxyribonucleic acid (DNA) called …

indinavir
atazanavir
burkitt's lymphoma
hodgkin's disease
tenofovir
  • 34 views
  • 24 Jan, 2021
  • 4 locations
Clinical Trial of a Novel Dose Adjustment Algorithm for Preventing Cytopenia-Related Delays During FOLFOX Chemotherapy

The study will test an intervention of an investigator-developed chemotherapy dose adjustment algorithm. The primary objective of this study is to evaluate the effectiveness of the chemotherapy dose adjustment algorithm for reducing unplanned delays in patients receiving FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin)-type chemotherapy, while maintaining acceptable chemotherapy dose-intensity.

oxaliplatin
fluorouracil
trastuzumab
adenocarcinoma
panitumumab
  • 0 views
  • 26 Oct, 2020
  • 1 location
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

This phase I/II trial studies the side effects and best dose of a radioactive agent linked to an antibody (211At-BC8-B10) followed by donor stem cell transplant in treating patients with high-risk acute leukemia or myelodysplastic syndrome that has come back (recurrent) or isn't responding to treatment (refractory). Monoclonal antibodies, such …

g-csf
cyclophosphamide
cell transplantation
leukemia
bone marrow transplant
  • 0 views
  • 17 Jan, 2021
  • 1 location